Pharmacogenetics of Buprenorphine/Naltrexone for Cocaine Dependence in the CURB Study

David A. Nielsen, PhD
Co-Lead Investigator
Baylor College of Medicine, Texas

Thomas R. Kosten, MD
Co-Lead Investigator
Baylor College of Medicine, Texas

This ancillary study is related to CTN-0048, "Cocaine Use Reduction with Buprenorphine (CURB)."

This study aims to test whether genetic markers in the mu, kappa, and nociceptin/orphanin FQ, OPRL1 receptors are associated with the efficacy of buprenorphine and naltrexone (BUP/NTX) for individuals with cocaine use disorder. Investigators hypothesize that patients with the functional mu polymorphism of OPRM1, rs1799971, A118G, which is non-synonymous Asn to Asp substitution, will have a greater reduction in cocaine use than those without this polymorphism. This hypothesis is based on the reduced rate of relapse during naltrexone treatment in alcoholic patients with this polymorphism compared to those without this polymorphism. The study will also explore several polymorphisms in the kappa and nociceptin/orphanin FQ neurotransmitter systems for their potential effects on treatment response to BUP/NTX based on protective associations of several of these polymorphisms with cocaine and other drug abuse.



Publications about CTN-0048-A-1

Texas (Lead Node) search www
  VA South Texas Health Care System search www
Greater New York search www
Albert Einstein College of Medicine search www
Bellevue Hospital Center search www
Ohio Valley search www
Maryhaven, Inc. search www
Pacific Northwest search www
Recovery Centers of King County search www
Pacific Region search www
  Bay Area Addiction Research and Treatment (BAART) search www
  Integrated Substance Abuse Programs (ISAP), UCLA search www
Southern Consortium search www
Atlanta VA Medical Center search www
Texas search www
VA South Texas Health Care System search www
Western States search www
Addiction Research & Treatment Services (ARTS) search
CODA, Inc. search www

Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 7/2013 --